Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1996 Jan;3(1):51–60. doi: 10.1128/cdli.3.1.51-60.1996

Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users.

J B Page 1, S Lai 1, M A Fletcher 1, R Patarca 1, P C Smith 1, H C Lai 1, N G Klimas 1
PMCID: PMC170247  PMID: 8770504

Abstract

In an ongoing prospective study of street-recruited intravenous drug users (IDUs) in Miami, Fla., 116 human immunodeficiency virus type 1 (HIV-1)-infected IDUs were monitored for up to 7 years. This provided an opportunity to evaluate baseline immunological parameters as potential predictors of survival among HIV-1-infected IDUs. As expected, HIV-1-infected IDUs who had an advanced stage of the disease (Centers for Disease Control and Prevention classification III or IV); p24 antigenemia; human T-cell leukemia virus type 1/2 seropositivity; low CD4 counts (< or = 200); low hemoglobin (< or = 14), high serum immunoglobulin A (IgA) (> 500 mg/dl), or high serum IgG (> or = 3,500 mg/dl) levels; or low proliferative responses to pokeweed mitogen (< or = 1,500 cpm) and to phytohemagglutinin (< or = 80,000 cpm) at baseline had worse survival rates. Results from multivariate Cox's models of survival showed that the baseline serum IgG level, serum IgA level, and CD4 count independently predict survival in HIV-1-infected IDUs. Cross-validation procedures verified the above-mentioned findings. These findings support the routine consideration of serum immunoglobulin levels in addition to CD4 count, especially in early evaluation of disease stage, as these evaluations may modify application of prophylaxis and treatment for HIV-1-infected IDUs. We recommend consideration of use of serum IgG and IgA as immunological markers for long-range prediction of survival in HIV-1-infected IDUs. These determinations are less onerous and more appropriate for use in field studies and financially less favored settings.

Full Text

The Full Text of this article is available as a PDF (227.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beral V., Peterman T. A., Berkelman R. L., Jaffe H. W. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990 Jan 20;335(8682):123–128. doi: 10.1016/0140-6736(90)90001-l. [DOI] [PubMed] [Google Scholar]
  2. Casabona J., Bosch A., Salas T., Sánchez E., Segura A. The effect of tuberculosis as a new AIDS definition criterion in epidemiological surveillance data from a south European area. J Acquir Immune Defic Syndr. 1990;3(3):272–277. [PubMed] [Google Scholar]
  3. De Gruttola V., Wulfsohn M., Fischl M. A., Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1993 Apr;6(4):359–365. [PubMed] [Google Scholar]
  4. Des Jarlais D. C., Friedman S. R., Marmor M., Cohen H., Mildvan D., Yancovitz S., Mathur U., el-Sadr W., Spira T. J., Garber J. Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS. 1987 Jul;1(2):105–111. [PubMed] [Google Scholar]
  5. Donahoe R. M., Falek A. Neuroimmunomodulation by opiates and other drugs of abuse: relationship to HIV infection and AIDS. Adv Biochem Psychopharmacol. 1988;44:145–158. [PubMed] [Google Scholar]
  6. Fahey J. L., Taylor J. M., Detels R., Hofmann B., Melmed R., Nishanian P., Giorgi J. V. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990 Jan 18;322(3):166–172. doi: 10.1056/NEJM199001183220305. [DOI] [PubMed] [Google Scholar]
  7. Farizo K. M., Buehler J. W., Chamberland M. E., Whyte B. M., Froelicher E. S., Hopkins S. G., Reed C. M., Mokotoff E. D., Cohn D. L., Troxler S. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA. 1992 Apr 1;267(13):1798–1805. [PubMed] [Google Scholar]
  8. Fernández-Cruz E., Desco M., Garcia Montes M., Longo N., Gonzalez B., Zabay J. M. Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS. 1990 Oct;4(10):987–994. doi: 10.1097/00002030-199010000-00007. [DOI] [PubMed] [Google Scholar]
  9. Fling J. A., Fischer J. R., Jr, Boswell R. N., Reid M. J. The relationship of serum IgA concentration to human immunodeficiency virus (HIV) infection: a cross-sectional study of HIV-seropositive individuals detected by screening in the United States Air Force. J Allergy Clin Immunol. 1988 Dec;82(6):965–970. doi: 10.1016/0091-6749(88)90132-7. [DOI] [PubMed] [Google Scholar]
  10. Herberman R. B., Djeu J., Kay H. D., Ortaldo J. R., Riccardi C., Bonnard G. D., Holden H. T., Fagnani R., Santoni A., Puccetti P. Natural killer cells: characteristics and regulation of activity. Immunol Rev. 1979;44:43–70. doi: 10.1111/j.1600-065x.1979.tb00267.x. [DOI] [PubMed] [Google Scholar]
  11. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  12. Homsy J., Meyer M., Tateno M., Clarkson S., Levy J. A. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science. 1989 Jun 16;244(4910):1357–1360. doi: 10.1126/science.2786647. [DOI] [PubMed] [Google Scholar]
  13. Klimas N. G., Page J. B., Patarca R., Chitwood D., Morgan R., Fletcher M. A. Effects of retroviral infections on immune function in African-American intravenous drug users. AIDS. 1993 Mar;7(3):331–335. doi: 10.1097/00002030-199303000-00004. [DOI] [PubMed] [Google Scholar]
  14. Korn E. L., Simon R. Measures of explained variation for survival data. Stat Med. 1990 May;9(5):487–503. doi: 10.1002/sim.4780090503. [DOI] [PubMed] [Google Scholar]
  15. Lucey D. R., Hendrix C. W., Andrzejewski C., Melcher G. P., Butzin C. A., Henry R., Wians F. H., Jr, Boswell R. N. Comparison by race of total serum IgG, IgA, and IgM with CD4+ T-cell counts in North American persons infected with the human immunodeficiency virus type 1. J Acquir Immune Defic Syndr. 1992;5(4):325–332. [PubMed] [Google Scholar]
  16. Minato N., Reid L., Cantor H., Lengyel P., Bloom B. R. Mode of regulation of natural killer cell activity by interferon. J Exp Med. 1980 Jul 1;152(1):124–137. doi: 10.1084/jem.152.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Morrow W. J., Wharton M., Stricker R. B., Levy J. A. Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. Clin Immunol Immunopathol. 1986 Sep;40(3):515–524. doi: 10.1016/0090-1229(86)90196-0. [DOI] [PubMed] [Google Scholar]
  18. Muñoz A., Vlahov D., Solomon L., Margolick J. B., Bareta J. C., Cohn S., Astemborski J., Nelson K. E. Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune Defic Syndr. 1992;5(7):694–700. [PubMed] [Google Scholar]
  19. Ortaldo J. R., Herberman R. B. Heterogeneity of natural killer cells. Annu Rev Immunol. 1984;2:359–394. doi: 10.1146/annurev.iy.02.040184.002043. [DOI] [PubMed] [Google Scholar]
  20. Page J. B., Lai S. H., Chitwood D. D., Klimas N. G., Smith P. C., Fletcher M. A. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet. 1990 Jun 16;335(8703):1439–1441. doi: 10.1016/0140-6736(90)91456-k. [DOI] [PubMed] [Google Scholar]
  21. Robinson W. E., Jr, Montefiori D. C., Mitchell W. M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet. 1988 Apr 9;1(8589):790–794. doi: 10.1016/s0140-6736(88)91657-1. [DOI] [PubMed] [Google Scholar]
  22. Schemper M. The relative importance of prognostic factors in studies of survival. Stat Med. 1993 Dec 30;12(24):2377–2382. doi: 10.1002/sim.4780122413. [DOI] [PubMed] [Google Scholar]
  23. Schnittman S. M., Lane H. C., Higgins S. E., Folks T., Fauci A. S. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science. 1986 Sep 5;233(4768):1084–1086. doi: 10.1126/science.3016902. [DOI] [PubMed] [Google Scholar]
  24. Selwyn P. A., Alcabes P., Hartel D., Buono D., Schoenbaum E. E., Klein R. S., Davenny K., Friedland G. H. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992 Dec 10;327(24):1697–1703. doi: 10.1056/NEJM199212103272401. [DOI] [PubMed] [Google Scholar]
  25. Stein D. S., Korvick J. A., Vermund S. H. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992 Feb;165(2):352–363. doi: 10.1093/infdis/165.2.352. [DOI] [PubMed] [Google Scholar]
  26. Stoneburner R. L., Des Jarlais D. C., Benezra D., Gorelkin L., Sotheran J. L., Friedman S. R., Schultz S., Marmor M., Mildvan D., Maslansky R. A larger spectrum of severe HIV-1--related disease in intravenous drug users in New York City. Science. 1988 Nov 11;242(4880):916–919. doi: 10.1126/science.3187532. [DOI] [PubMed] [Google Scholar]
  27. Stricker R. B., McHugh T. M., Moody D. J., Morrow W. J., Stites D. P., Shuman M. A., Levy J. A. An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells. 1987 Jun 25-Jul 1Nature. 327(6124):710–713. doi: 10.1038/327710a0. [DOI] [PubMed] [Google Scholar]
  28. Takeda A., Ennis F. A. FcR-mediated enhancement of HIV-1 infection by antibody. AIDS Res Hum Retroviruses. 1990 Aug;6(8):999–1004. doi: 10.1089/aid.1990.6.999. [DOI] [PubMed] [Google Scholar]
  29. Takeda A., Tuazon C. U., Ennis F. A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science. 1988 Oct 28;242(4878):580–583. doi: 10.1126/science.2972065. [DOI] [PubMed] [Google Scholar]
  30. Verweij P. J., Van Houwelingen H. C. Cross-validation in survival analysis. Stat Med. 1993 Dec 30;12(24):2305–2314. doi: 10.1002/sim.4780122407. [DOI] [PubMed] [Google Scholar]
  31. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  32. Yarchoan R., Redfield R. R., Broder S. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. J Clin Invest. 1986 Aug;78(2):439–447. doi: 10.1172/JCI112595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zangerle R., Fuchs D., Reibnegger G., Fritsch P., Wachter H. Markers for disease progression in intravenous drug users infected with HIV-1. AIDS. 1991 Aug;5(8):985–991. doi: 10.1097/00002030-199108000-00010. [DOI] [PubMed] [Google Scholar]
  34. Zolla-Pazner S., Des Jarlais D. C., Friedman S. R., Spira T. J., Marmor M., Holzman R., Mildvan D., Yancovitz S., Mathur-Wagh U., Garber J. Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5404–5408. doi: 10.1073/pnas.84.15.5404. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES